resTORbio, Inc. (NASDAQ:TORC) – Investment analysts at Svb Leerink issued their Q1 2019 earnings estimates for shares of resTORbio in a research report issued to clients and investors on Monday, March 25th. Svb Leerink analyst G. Porges expects that the company will post earnings of ($0.45) per share for the quarter. Svb Leerink currently has a “Outperform” rating on the stock. Svb Leerink also issued estimates for resTORbio’s Q2 2019 earnings at ($0.48) EPS, Q3 2019 earnings at ($0.49) EPS, Q4 2019 earnings at ($0.62) EPS, FY2019 earnings at ($2.05) EPS, FY2020 earnings at ($2.28) EPS, FY2021 earnings at ($1.97) EPS, FY2022 earnings at $1.13 EPS and FY2023 earnings at $4.06 EPS.

resTORbio (NASDAQ:TORC) last released its quarterly earnings results on Monday, March 18th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.34) by $0.13.

A number of other analysts also recently issued reports on TORC. Wedbush reaffirmed an “outperform” rating on shares of resTORbio in a research report on Monday, March 18th. Zacks Investment Research downgraded resTORbio from a “buy” rating to a “hold” rating in a research report on Thursday, February 21st. Finally, ValuEngine downgraded resTORbio from a “buy” rating to a “hold” rating in a research report on Friday, December 21st. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company. resTORbio has a consensus rating of “Hold” and a consensus price target of $14.00.

NASDAQ:TORC opened at $7.02 on Wednesday. The stock has a market capitalization of $241.50 million, a P/E ratio of -4.94 and a beta of 3.12. resTORbio has a 52-week low of $6.21 and a 52-week high of $20.59.

Several large investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp increased its position in shares of resTORbio by 9.9% in the fourth quarter. Bank of New York Mellon Corp now owns 27,788 shares of the company’s stock valued at $239,000 after acquiring an additional 2,497 shares during the last quarter. Bank of America Corp DE increased its position in shares of resTORbio by 6.5% in the fourth quarter. Bank of America Corp DE now owns 46,266 shares of the company’s stock valued at $398,000 after acquiring an additional 2,809 shares during the last quarter. Vanguard Group Inc. increased its position in shares of resTORbio by 2.7% in the third quarter. Vanguard Group Inc. now owns 288,490 shares of the company’s stock valued at $4,368,000 after acquiring an additional 7,545 shares during the last quarter. Vanguard Group Inc increased its position in shares of resTORbio by 2.7% in the third quarter. Vanguard Group Inc now owns 288,490 shares of the company’s stock valued at $4,368,000 after acquiring an additional 7,545 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of resTORbio by 21.9% in the fourth quarter. Geode Capital Management LLC now owns 86,442 shares of the company’s stock valued at $745,000 after acquiring an additional 15,514 shares during the last quarter. 41.72% of the stock is currently owned by institutional investors and hedge funds.

resTORbio Company Profile

resTORbio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. Its lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems.

Further Reading: Straddles

Earnings History and Estimates for resTORbio (NASDAQ:TORC)

Receive News & Ratings for resTORbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for resTORbio and related companies with MarketBeat.com's FREE daily email newsletter.